Elevance Health is set to report second-quarter 2026 results on July 15, with the Zacks Consensus Estimate pegging earnings at $6.18 per share on revenues of $48.45 billion, implying a 30.1% drop in earnings and a 2% revenue decline year over year. The Health Benefits segment's operating income is expected to plunge 34.7%, while the benefit expense ratio is seen rising to 89.4 from 88.9 a year ago, further pressuring profitability. Membership declines are also anticipated, with Commercial Individual memberships forecast to fall 10% and Medicaid memberships down 5.8%, though Commercial Fee-based memberships are projected to grow 1.9%. Despite these challenges, Elevance has beaten earnings estimates in three of the last four quarters with an average surprise of 10.6%, and the stock carries a Zacks Rank of 2.
Elevance Health IncQ2 earnings expected to drop 30.1% with revenue decline and rising benefit expense ratio
Cardinal Health Inc
Alcon AG
ProMIS Neurosciences Inc.